

ACQUIRE
BUSINESS-CRITICAL
MARKET ACCESS
COMPETENCIES



LEARN from Pharma's
international top experts

Lieven Annemans

How to Optimally Manage HTA Criteria & Processes in Europe

Best practices, Trends & Opportunities

LEARN from interacting
with your industry peers



The HTA course provides a great guidance of possible criteria and now the company should work to achieve best results. Great presenter encouraging discussions as always."

Celgene

Martina Jerabkova

Associate Director Global Market Access
Switzerland



How to Optimally Manage HTA Criteria & Processes in Europe

Best Practices, Trends & Opportunities

Learn

- The meaning of HTA and the key decision-making processes of HTA in Europe.
- The health economic principles used in HTAs and the interpretation by HTA bodies.
- How to deal with the many possible criteria for assessment and their relative weights.
- How to prepare all departments within a company for the different HTA processes.
- Pros & cons of a possible joint clinical assessment in Europe.
- The solutions to the most common problems and mistakes when optimising the quality of the evidence.



The Expert

Lieven Annemans

- Prof. Dr. Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of HTAs and is actively involved in HTA on a European level.
- A unique profile: academic professor, past-president of ISPOR, advisor to policy makers, trainer and consultant.
- Highly respected for his vast international and cross-therapeutic experience, Lieven is a much sought-after advisor and educator to health policy makers and the innovative healthcare industry.
- Author of *Health economics for non-economists* (Pelckmans Pro, 2018).

Dates & Locations

1 June 2023 (live online)

28 November 2023 (live online)

Visit www.celforpharma.com for registration fees and updates.

Additional Benefits

- Learn from Europe's most entertaining health economics and HTA expert.
- Exchange experiences and discuss issues with your peers from other companies, functions, therapy areas and countries.

What Participants Say About This Course



The course was very complete and clear to understand better how to fulfil the market access challenges all over European countries. Lieven was very nice as educator to explain complex concepts in a very easy way."

Laboratoires Théa

Caroline Casanovas
PRMA & HEOR Manager
France (June 2022)



A lot of course materials and practical examples presented in an understandable manner with enough humour to keep us going. Lieven is an entertaining and knowledgeable trainer who answered all of our questions and offered excellent interaction opportunities. I really learned a lot on HTA and health economics. Thanks CELforPharma, and thank you Lieven!"

Takeda

Tom Vanormelingen
Field Market Access Manager
The Netherlands (November 2021)



The course was well-structured and well presented by Prof. Lieven Annemans who gave us clear explanations and used illustrative materials to help us better grasp the key concepts of HTA. It was a very interactive course during the presentations and break-out sessions. Thanks and well done for a great training."

Amgen

Vincent Martichou
Government Affairs Manager ELMAC
Belgium (November 2021)

Agenda

All courses are held in CET/Brussels Time. Please check the Dates & Locations section on our website for the exact start and end times, or send an email to kealeigh.steel@celforpharma.com.

Welcome & General Introduction (~30 min)

Understand What is HTA - What it is Not (~1 h)

- Definitions
- Different types of HTA and the wide variety across countries
- Key principles of HTA

Thresholds Used by HTA Bodies in ICER-based Decision Making (~1 h)

- Recap of basic health economic principles (e.g. QALY, ICER ...)
- The variety of thresholds approaches used across HTA bodies

Selecting from the Wide Range of Decision Criteria - part 1 (~1 h)

- Exploring the assessment criteria in HTA and their relative weight
- Providing evidence for all criteria

Lunch Break

Selecting from the Wide Range of Decision Criteria - part 2 (~1 h)

- Using Multi-Criteria Decision Analysis (MCDA) to determine weights and influence decision making
- Trading off between criteria

Effectively Working with HTA Processes Across Europe (~1 h 45 min)

- The optimal HTA process: does it exist? – Learn from differences between countries
- The benefits and risks of international cooperation
- 'Adaptive' HTA and contracts based on outcomes guarantees

Summary of Dos and Don'ts & Final Discussion (~15 min)

Closing

Registration Form

Complete the below form and email to aswaan@celforpharma.com or fax to +32 2 721 13 82 or go to www.celforpharma.com and complete the online registration form.



Questions?

Annelies Swaan
+32 2 709 01 42
aswaan@celforpharma.com

Course(s)

Course Title
Course Date(s)

Registration Fee

Visit our website www.celforpharma.com for information about the early bird fee and full fee, group discounts, etc.

Participant Details

Title Email
First Name Mobile Number
Last Name Country of Work
Job Title

Company Details

Company Name
VAT Number
Invoicing Address:
Street Address
City/Province
Postcode
Country

Payment

Payment Method Bank Transfer (+3%) Credit Card
PO Number (optional)

Confirm Registration

In order to complete the registration, please tick the following box(es):

- I, the participant(s), have read and accept CELforPharma's Transfer & Cancellation Policy (www.celforpharma.com/transfer-cancellation-policy) and Privacy Policy (www.celforpharma.com/we-value-your-privacy)
- I accept that CELforPharma regularly sends me information by email on topics discussed within their website (www.celforpharma.com) and relevant to my function, under the condition that I can unsubscribe at any time. I accept that relevant personal details are stored in a database for that purpose, as per CELforPharma's Privacy Policy (www.celforpharma.com/we-value-your-privacy), of which I accept the terms.